377 related articles for article (PubMed ID: 17517451)
1. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003.
Soriano-Gabarró M; Toé L; Tiendrebeogo SR; Nelson CB; Dabal M; Djingarey MH; Plikaytis B; Rosenstein N;
Vaccine; 2007 Sep; 25 Suppl 1():A92-6. PubMed ID: 17517451
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal carriage and immunity in western Burkina Faso, 2003.
Yaro S; Traoré Y; Tarnagda Z; Sangaré L; NjanpopLafourcade BM; Drabo A; Findlow H; Borrow R; Nicolas P; Gessner BD; Mueller JE
Vaccine; 2007 Sep; 25 Suppl 1():A42-6. PubMed ID: 17559988
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso.
Bentsi-Enchill AD; Zongo I; Khamassi S; Pless R; Thombiano R; Tiéndrebéogo S; Nelson CB; Duclos P
Vaccine; 2007 Sep; 25 Suppl 1():A72-8. PubMed ID: 17544552
[TBL] [Abstract][Full Text] [Related]
5. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.
Traoré Y; Njanpop-Lafourcade BM; Adjogble KL; Lourd M; Yaro S; Nacro B; Drabo A; Parent du Châtelet I; Mueller JE; Taha MK; Borrow R; Nicolas P; Alonso JM; Gessner BD
Clin Infect Dis; 2006 Oct; 43(7):817-22. PubMed ID: 16941360
[TBL] [Abstract][Full Text] [Related]
6. Issues surrounding standardization of meningococcal group W135 serology.
Balmer P; Borrow R
Vaccine; 2007 Sep; 25 Suppl 1():A63-8. PubMed ID: 17544550
[TBL] [Abstract][Full Text] [Related]
7. The outbreak of meningitis due to Neisseria meningitidis W135 in 2003 in Burkina Faso and the national response: main lessons learnt.
Zombré S; Hacen MM; Ouango G; Sanou S; Adamou Y; Koumaré B; Kondé MK
Vaccine; 2007 Sep; 25 Suppl 1():A69-71. PubMed ID: 17630052
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.
Mueller JE; Borrow R; Gessner BD
Expert Rev Vaccines; 2006 Jun; 5(3):319-36. PubMed ID: 16827617
[TBL] [Abstract][Full Text] [Related]
9. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002.
Raghunathan PL; Jones JD; Tiendrebéogo SR; Sanou I; Sangaré L; Kouanda S; Dabal M; Lingani C; Elie CM; Johnson S; Ari M; Martinez J; Chatt J; Sidibe K; Schmink S; Mayer LW; Kondé MK; Djingarey MH; Popovic T; Plikaytis BD; Carlone GM; Rosenstein N; Soriano-Gabarró M
J Infect Dis; 2006 Mar; 193(5):607-16. PubMed ID: 16453255
[TBL] [Abstract][Full Text] [Related]
10. Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003.
Mueller JE; Yaro S; Traore Y; Sangare L; Tarnagda Z; Njanpop-Lafourcade BM; Borrow R; Gessner BD
J Infect Dis; 2006 Mar; 193(6):812-20. PubMed ID: 16479516
[TBL] [Abstract][Full Text] [Related]
11. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing.
Parent du Châtelet I; Traore Y; Gessner BD; Antignac A; Naccro B; Njanpop-Lafourcade BM; Ouedraogo MS; Tiendrebeogo SR; Varon E; Taha MK
Clin Infect Dis; 2005 Jan; 40(1):17-25. PubMed ID: 15614687
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
13. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso.
Decosas J; Koama JB
Lancet Infect Dis; 2002 Dec; 2(12):763-5. PubMed ID: 12467693
[TBL] [Abstract][Full Text] [Related]
14. [Clonal expansion of Neisseria meningitidis W135. Epidemiological implications for the African meningitis belt].
du Châtelet IP; Alonso JM; Taha MK
Bull Soc Pathol Exot; 2002 Dec; 95(5):323-4; discussion 324-5. PubMed ID: 12696368
[TBL] [Abstract][Full Text] [Related]
15. Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia.
Aseffa A; Bedru A; Yamuah L; Arga D; Worku A; Chandramohan D; Nelson CB; Engers HD
Vaccine; 2007 Sep; 25 Suppl 1():A79-82. PubMed ID: 17548138
[TBL] [Abstract][Full Text] [Related]
16. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.
Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA
Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435
[TBL] [Abstract][Full Text] [Related]
17. [Meningococcemia and meningitis due to Neisseria meningitidis W135 developed in two cases vaccinated with bivalent (A/C) meningococcal vaccine].
Turhan V; Acar A; Kılıç A; Budak S; Oncül O; Haznedaroğlu T; Görenek L
Mikrobiyol Bul; 2010 Jul; 44(3):473-8. PubMed ID: 21063998
[TBL] [Abstract][Full Text] [Related]
18. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002.
Koumaré B; Ouedraogo-Traoré R; Sanou I; Yada AA; Sow I; Lusamba PS; Traoré E; Dabal M; Santamaria M; Hacen MM; Kaboré AB; Caugant DA
Vaccine; 2007 Sep; 25 Suppl 1():A37-41. PubMed ID: 17521783
[TBL] [Abstract][Full Text] [Related]
19. Infectious disease. Shortage of meningitis vaccine forces triage in Burkina Faso.
Vogel G
Science; 2003 Mar; 299(5612):1499-501. PubMed ID: 12624241
[No Abstract] [Full Text] [Related]
20. Meningitis epidemics in Africa: a brief overview.
Teyssou R; Muros-Le Rouzic E
Vaccine; 2007 Sep; 25 Suppl 1():A3-7. PubMed ID: 17643560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
